SAN DIEGO, Calif./ACCESSWIRE/May 23, 2022/ Dermata Therapeutics, Inc. (NASDAQ: DRMA) (“Derry” or the “Company”), a clinical-stage biotechnology company specializing in the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, President of Dermata Board of Directors, Chairman and Chief Executive Officer will present an overview of the company at the HC Wainwright Global Investment Conference to be held May 23-26, 2022. The in-person venue for the hybrid event is the Fontainebleau hotel in Miami Beach at 4441 Collins Avenue. Virtual attendance will be staged simultaneously as a live stream and available on demand.
During the presentation, Mr. Proehl will discuss the company’s progress on its lead product candidate, DMT310, a once-a-week treatment for moderate to severe acne, and the company’s new program, DMT410, for topical administration of botulinum toxin.
The on-demand presentation will be available beginning at 7 a.m. ET on Tuesday, May 24, 2022 and can be accessed by registering for the conference at the following link. Management will also participate in one-to-one and small group virtual meetings during the conference. Those interested in meeting with management may contact Dermata’s Investor Relations Representative listed below.
About Dermata Therapeutics
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions. The Company’s lead product candidate, DMT310, is the first product candidate developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally occurring freshwater sponge with multiple unique mechanisms of action. DMT310 is in clinical development for the topical treatment of acne, psoriasis and rosacea. Dermata’s second product candidate, DMT410, uses its Spongilla technology as a new method of topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit our website.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors, including, but not limited to, statements relating to: the potential development and commercialization of product candidates; the ability of the Company’s product candidates to meet applicable endpoints in clinical trials; whether the results of the Company’s product candidates will lead to future product development; and whether the Company will be able to obtain adequate funding for the future development of its product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of these statements due to a variety of factors, including the risks and uncertainties inherent in the development, approval and commercialization of drugs, and the fact that Past clinical trial results may not be indicative of future trials. results. For a discussion of these and other factors, please refer to Dermata’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This cautionary statement is made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update updates this press release to reflect current events or circumstances. after the date hereof, except as required by law.
Senior Director, Legal and Business Development
THE SOURCE: Therapeutic dermatology
See the source version on accesswire.com: